

Index

A

- Aardvark, 147
- AD. *See* Alzheimer's disease
- Adenomatous polyposis coli (APC), 9–11, 16
 - axon terminal remodeling, 287
 - β -catenin
 - binding sites, 94
 - destruction role, 93–98
 - mutation in cancer, 254, 395–396
- Adenomatous polyposis coli down-regulated-1 (APCDD1), Wnt signaling inhibition, 51
- ALV. *See* Avian leukosis virus
- Alzheimer's disease (AD)
 - LRP6 Alzheimer's disease variants, 293
 - Wnt signaling and therapeutic targeting, 426, 430
- Androgen receptor (AR)
 - β -catenin binding, 118
 - Wnt cross-talk in cancer, 400
- AP-1, β -catenin-independent Wnt signaling, 136
- APC. *See* Adenomatous polyposis coli
- APCDD1. *See* Adenomatous polyposis coli down-regulated-1
- AR. *See* Androgen receptor
- Armadillo, 10–11
- Arrow
 - history of study, 12
 - homologs. *See* Lipoprotein receptor-related protein
 - mutants, 69
 - structure, 70
- Avian leukosis virus (ALV), history of study, 3
- Axin, 11, 14, 34, 70
 - β -catenin
 - destruction complex, 92–93
 - phosphorylation inhibition after receptor activation, 79–82
 - domains, 92–93
 - recruitment, 75
 - therapeutic targeting, 435
 - tumor suppressor genes, 396
 - Wnt signaling overview, 74
- Axis specification
 - anteroposterior axis specification
 - Dkk1 and patterning, 42–43, 45, 201–202, 221
 - mouse, 220–221
 - zygotic Wnt signaling, 201–202
 - cross-talk between Wnt and other pathways, 205–207
 - dorsoventral axis specification, 199–201, 203

- pathway switch mechanisms, 204–205
 - prospects for study, 207
 - TCF function regulation, 203–204
 - transcriptional targets of Wnt pathway, 202–203
 - Wnt signaling overview, 197–199
- Axon. *See* Central nervous system

B

- BAR-1, 184–186
- Basal cell carcinoma (BCC), Wnt signaling, 338
- BCC. *See* Basal cell carcinoma
- B cell, Wnt signaling in development, 314–315
- β -Catenin
 - APC interactions, 9–10
 - Caenorhabditis elegans*
 - BAR-1 pathway, 186
 - β -catenin-independent signaling, 186
 - destruction complex, 184
 - types, 184–186
 - Wnt/ β -catenin asymmetry pathway, 188–189
 - canonical Wnt signaling
 - outside of TCF/LEF, 118–119
 - overview, 65–66
 - destruction complex
 - APC role, 93–94
 - axin as phosphorylation scaffold, 92
 - β -catenin phosphorylation, 94–95
 - cycling, 95–96
 - kinases, 91
 - localization, 98–99
 - overview, 89–90
 - proteasomal degradation, 90–91, 96–97
 - sequestration of β -catenin, 97–98
 - tumor suppressor genes, 396–397
 - embryonic stem cell
 - Oct4– β -catenin interaction, 240–241
 - stability role in glycogen synthase kinase-3 inhibition, 239–240
 - Tcf-dependent mechanisms and Wnt-stabilized β -catenin, 242–246
 - histone modification regulation, 112–114
 - phosphorylation inhibition after receptor activation, 79–82
 - signaling cascade from cell surface to nucleus, 10–11
 - TCF/LEF binding domain, 106–107
 - transcriptional targets in axis specification, 202–203

Index

- Biglycan, 32
BMP. *See* Bone morphogenetic proteins
Bone
 anatomy, 267
 development
 Dickkopf role, 45–46
 overview, 265–267
 Wnt/ β -catenin signaling in cartilage and joint formation, 271–272
 lithium effects, 436
 Wnt/ β -catenin signaling
 cancer and metastasis, 276–277
 fracture healing, 275–276
 human bone disease, 268–270
 osteoblast
 differentiation and maturation, 270–271
 function, 272–274
 osteocyte, 274–275
 regenerative medicine, 432
Bone morphogenetic proteins (BMPs), axis specification and Wnt cross-talk, 205–207
Brachyury, 148
Brain. *See* Central nervous system
Breast cancer. *See also* Mammary gland
 growth and Wnt signaling
 E-cadherin loss, 354–355
 nuclear β -catenin, 354
 overview, 352–354
 Wnt-dependent subpopulations, 354
 human cell studies of Wnt signaling, 402–403

C
Caenorhabditis elegans, Wnt signaling
 β -catenin-independent signaling, 186
 components of canonical signaling
 β -catenins, 184–186
 BAR-1 pathway, 186
 destruction complex, 184
 Dishevelled, 184
 Frizzled, 183–184
 table, 180
 TCF/LEF, 185–186
 Wnt ligands and inhibitors, 181–183
 conserved metazoan components, 180–181
 embryonic endoderm induction, P2/EMS signaling, 189–191
 neuromuscular junction development. *See* Neuromuscular junction
 overview, 179–180
 prospects for study, 191–192
 QL neuroblast progeny migration regulation, 186–188
 Wnt/ β -catenin asymmetry pathway, 188–189
E-Cadherin, loss in breast cancer, 354–355
Calcium/calmodulin-dependent kinase-II (CaMKII), synaptic function, 289–290
Calcium flux, β -catenin-independent Wnt signaling, 137
CaMKII. *See* Calcium/calmodulin-dependent kinase-II
Cancer. *See also specific cancers*
 history of Wnt studies, 9–10
 oncogenes, 395–396
 tumor suppressor genes, 395–397
 Wnt signaling
 chronic injury and prolonged Wnt signaling, 415–416
 cross-talk with other pathways, 399–401
 defects, 398, 424
 epigenetic modulation, 397–399
 human cell studies, 401–404
 therapeutic targeting
 non-canonical signaling, 425–426
 overview, 424
 patient survival correlation with β -catenin, 424–425
Cancer stem cell (CSC)
 intestine, 258–259
 stomach, 259
Casein kinase-1 (CK1)
 β -catenin destruction complex, 91
 phosphorylation of LRP6, 72, 75–78
 therapeutic targeting, 436
CBP. *See* CREB-binding protein
Cdc42, β -catenin-independent Wnt signaling, 135–136
CE. *See* Convergent extension
Central nervous system (CNS), Wnt function
 axon guidance, 284–285
 axon terminal remodeling, 287
 disease and deregulation, 293
 forebrain development
 cell adhesion, 303–304
 expression patterns, 298–299
 lamination, 304
 overview, 297–298
 patterning, 299–302
 prospects for study, 304–305
 radial glia regulation and intermediate progenitor fate, 302–303
 ventral forebrain neurogenesis, 304
 neuronal activity regulation of Wnt release and receptor localization, 290–291
 prospects for study, 293–294
 synapse formation
 excitatory versus inhibitory synapses, 289–290
 overview, 287
 postsynaptic assembly, 289
 presynaptic assembly, 287–289
 synapse plasticity, 291–293
 topographical map formation in brain, 285–287

- Cerberus
 knockout mice, 44
 overview, 49–50
- CK1. *See* Casein kinase-1
- Clozapine, Wnt signaling effects, 436
- CNS. *See* Central nervous system
- Convergent extension (CE)
 β -catenin-independent Wnt signaling, 129, 135–136
 core proteins, 135
 effectors, 135–136
- CREB-binding protein (CBP), cancer mutations, 397
- Cripto, 221
- CSC. *See* Cancer stem cell
- D**
- DACT3, repression in colorectal cancer, 399
- Derailed, history of study, 13
- Destruction complex. *See* β -Catenin
- Development. *See* Axis specification; Bone; Central nervous system; Mouse development; Neuromuscular junction; Skin
- Dickkopf (Dkk)
 Alzheimer's disease expression, 293
 cancer expression of DKK1, 276–277
 developmental function
 anteroposterior patterning and Dkk1, 42–43, 45, 201–202, 221
 limb, bone, and eye formation, 45–46
 Dkk2 inhibition and activation of Wnt signaling pathway, 42
 injury repair therapeutic targeting of DKK1, 417
 knockout mice, 44
 mechanism of action, 40–42
 pathology, 46
 structure, 40
 therapeutic targeting, 434, 437
- DISC1*, 293, 426
- Dishevelled (DVL)
 β -catenin-independent Wnt signaling, 132–133
 Caenorhabditis elegans, 184
 dorsoventral axis specification, 200
 Frizzled interactions, 74–75
 structure, 67
 therapeutic targeting, 434–435
 Wnt signaling overview, 73–74
- DKK. *See* Dickkopf
- Drosophila*. *See* Neuromuscular junction; Wingless
- DVL. *See* Dishevelled
- E**
- EGFR. *See* Epidermal growth factor receptor
- Embryonic stem cell (ESC)
 comparison of mouse and human, 234–235
 culture, 233–234
 transcription factors in self-renewal, 235
- Wnt signaling
 cell differentiation inhibition, 235–237
 glycogen synthase kinase-3 inhibition
 β -catenin stability role, 239–240
 pluripotency state dependence, 238–239
 Oct4– β -catenin interaction, 240–241
 prospects for study, 246
 self-renewal stimulation, 237–238
 Tcf-dependent mechanisms
 Tcf3 in self-renewal, 241–242
 Wnt-stabilized β -catenin, 242–246
- Emx2, forebrain patterning, 301–302
- Ephrin, topographical map formation in brain, 286–287
- Epidermal growth factor receptor (EGFR), 166, 400
- Epigenetics, modulation of Wnt signaling, 397–399
- ESC. *See* Embryonic stem cell
- Evi. *See* *Wntless*
- Evolution, Wnt pathway
 bilaterians
 Deuterostomia, 153–154
 Ecdysozoa, 153
 gene distribution, 152
 Lophotrochozoa, 151, 153
 gene synteny and evolution, 154
 Hydra organizer
 local restriction, 157
 short- and long-range signaling, 155–157
 metazoan conserved elements, 180–181
 overview, 145–146
 pre-bilaterians
 Cnidaria, 150–151
 Ctenophora, 150
 overview, 148
 Placozoa, 149–150
 Porifera, 148–149
 pre-metazoans
 ligands of Wnt, 146
 receptors and mediators, 146–148
 transcription factors and target genes, 148
- F**
- Familial adenomatous polyposis (FAP)
 gene mutations. *See* Adenomatous polyposis coli
 Wnt pathway
 activating mutations, 254
 therapeutic targeting, 432–433
- FAP. *See* Familial adenomatous polyposis
- FDH. *See* Focal dermal hypoplasia
- FGF. *See* Fibroblast growth factor
- Fibroblast growth factor (FGF)
 axis specification and Wnt cross-talk, 206–207
 forebrain patterning, 301
 skin development, 319
- Focal dermal hypoplasia (FDH), 28

Index

Fracture, Wnt/ β -catenin signaling in healing, 275–276

Frizzled

- axon guidance, 284
 - β -catenin-independent Wnt signaling, 131–132
 - Caenorhabditis elegans*, 183–184
 - complex with Wnt and LRP5/6, 72–73
 - Dishevelled interactions, 74–75
 - history of study, 11–12
 - human genes, 66
 - neuromuscular junction development, 383–384
 - planar cell polarity role, 66
 - presynaptic assembly role, 288
 - therapeutic targeting, 434
 - trafficking, 31
 - Wnt–cysteine-rich domain interactions, 66–69
- Fumagillin, Wnt signaling effects, 438

G

Gastrulation, mouse Wnt signaling, 219–221

Gli1, forebrain patterning, 300

Glycogen synthase kinase-3 (GSK-3), 10, 34

β -catenin

- destruction complex, 91
 - phosphorylation inhibition after receptor activation, 79–82
- embryonic stem cell inhibition
- β -catenin stability role, 239–240
 - pluripotency state dependence, 238–239
- evolution, 146–147
- inhibitors, 436–437
- phosphorylation of LRP6, 75–76

Glypicans, 32

Gpr49. *See* Lgr5

G-proteins, β -catenin-independent Wnt signaling, 136–137

GSK-3. *See* Glycogen synthase kinase-3

H

Hair follicle (HF), Wnt signaling

- anatomy, 320
- cycling changes, 328–333
- development, 319–322, 328
- diseases, 337–338
- mouse mutation models, 323–327
- orientation in mouse, 225
- prospects for study, 338–339

Hematopoietic stem cell (HSC)

- hematopoiesis
 - overview, 309–310
 - Wnt signaling activation, 310–312
- lymphocyte development and Wnt signaling, 314–315
- niche, 311–312
- Wnt signaling manipulation

- gain-of-function studies, 312–313

- loss-of-function studies, 313–314

HF. *See* Hair follicle

HIPK2, phosphorylation of TCF/LEF, 116–117

Histone modification, regulation by TCF/LEF- β -catenin, 112–114

HIV. *See* Human immunodeficiency virus

HMP-2, 184–185

HSC. *See* Hematopoietic stem cell

Human immunodeficiency virus (HIV), Wnt signaling, 423

I

IGFBP-4. *See* Insulin-like growth factor-binding protein-4

Implantation, mouse Wnt signaling, 218

Inflammation, Wnt signaling, 413–414

Injury repair, Wnt signaling

- chronic injury, prolonged signaling, and cancer, 415–416

- fracture, 275–276

- inflammatory response, 413–414

- overview, 409–411

- prospects for study, 417–418

- regeneration of tissues

 - capacity across species, 410

 - Wnt signaling, 411–412

- therapeutic applications, 416–417

- wound repair phase response

 - initial phase, 412–413

 - proliferative phase, 414–415

Insulin-like growth factor-binding protein-4 (IGFBP-4)

- knockout mice, 44

- Wnt signaling mediation, 50

Int1

- developmental genetics, 6–7

- history of study, 3–8

- knockout mouse, 7–8

- mechanism elucidation, 5–6

- molecular cloning, 3–5

- Wnt1 renaming, 8, 25

Intestinal stem cell

- anatomy overview, 252–253

- cancer stem cells, 258–259

- characteristics, 254–257

- derivation, 431

- maintenance by TCF4, 16

- markers, 255–257

- R-spondin signaling mediation by Lgr receptors, 259–260

- Wnt signaling

 - activating mutations in cancer, 254

 - crypt self-renewal, 253–254

IWP, 34

IWR, 34

J

JNK. *See* Jun N-terminal kinase
Jun N-terminal kinase (JNK), β -catenin-independent Wnt signaling, 135–136

K

Kremen, Dickkopf binding, 40–42

L

LEF. *See* TCF/LEF
Leukemia, Wnt signaling
 myeloid leukemia, 315–316
 T-cell leukemia, 316
Lgr5
 gastric stem cell expression, 257–258
 intestinal stem cell expression, 255–257
 R-spondin signaling mediation by Lgr receptors, 259–260
Lhx2, forebrain patterning, 301
Lin-17, 389
Lin-44, 388
Lipoprotein receptor-related protein (LRP)
 Dickkopf binding, 40–42
 history of study, 12
 LRP5/6
 Alzheimer's disease LRP6 variants, 293
 complex with Frizzled and Wnt, 72–73
 extracellular domain, 69, 71
 mouse mutant studies of development, 220–221
 osteoporosis pseudoglioma syndrome LRP5 mutations, 268–269
 phosphorylation of LRP6
 axin recruitment, 75
 kinases and regulation, 75–78
 models, 77
 sites, 72
 signalosome, 78–79
 structure, 70
 Wnt-binding surfaces of LRP6, 71–72
 mutations, 17
 R-spondin binding, 52–53
 therapeutic targeting, 434, 437
LIT1/NLK, phosphorylation of TCF/LEF, 116–117
Lithium, Wnt signaling effects, 436
LRP. *See* Lipoprotein receptor-related protein
Lung cancer, human cell studies of Wnt signaling, 403
Lymphoid enhancer factor. *See* TCF/LEF
Lymphoma, Wnt signaling, 316

M

Mammary gland. *See also* Breast cancer
 anatomy in mouse, 346

 canonical versus non-canonical Wnt signaling, 350–352
 cell fate plasticity and Wnt signaling, 347–349
 expression and function of cell surface Wnt signaling components, 356–365
 mouse models for Wnt studies, 345–347
 prospects for study, 355, 366
 stem cell niche and Wnt signaling, 349–350
 Wnt4 function, 352
MBOAT. *See* Membrane-bound *O*-acyltransferases
Meetings, Wnt research, 14–16
Melanocyte, Wnt signaling, 335–337
Membrane-bound *O*-acyltransferases (MBOAT), Wnt processing, 28
Microphthalmia-associated transcription factor (MITF), 335–337
MIG-14. *See* *Wntless*
MITE. *See* Microphthalmia-associated transcription factor
MMTV. *See* Mouse mammary tumor virus
MOM1. *See* Porcupine
MOM2. *See* Wnt
MOM5. *See* Frizzled
Morphogenesis, mouse non-canonical Wnt signaling, 225
Mouse development
 canonical Wnt signaling in early development
 anteroposterior axis specification, 220–221
 gastrulation, 219–221
 implantation, 218
 overview, 217–218
 suppression in anterior patterning, 221
 tail bud formation, somitogenesis, and left-right determination, 222–223
 neuromuscular junction. *See* Neuromuscular junction
 planar cell polarity and non-canonical Wnt signaling
 epiblast cell polarity, 223–224
 hair follicle orientation, 225
 limb development, 226–228
 morphogenesis, 225
 neural tube closure, 225
 nodal cilia, 224
 overview, 223
 stereociliary bundle orientation, 224–225
 prospects for study, 228
Mouse mammary tumor virus (MMTV), history of study, 2–5, 9
c-Myc, history of study, 3

N

Nanog, embryonic stem cell self-renewal, 235
Neural tube, closure and mouse non-canonical Wnt signaling, 225

Index

- Neuromuscular junction (NMJ)
 invertebrate development and Wnt signaling
 Caenorhabditis elegans, 388–389
 Drosophila larva, 381–388
 vertebrate development
 overview, 376
 Wnt signaling
 components, 376–377
 negative regulation, 380–381
 positive regulation, 377–380
 Wnt signaling
 overview, 373–375
 prospects for study, 389–390
- Nexins, sorting nexins, 31
- NFAT, β -catenin-independent Wnt signaling, 137
- NMJ. *See* Neuromuscular junction
- Nodal, 220, 223
- Norrin
 developmental function, 55
 knockout mice, 45
 Wnt signaling activation, 55
- Notch, Wnt cross-talk in cancer, 400–401
- O**
- Oct4
 β -catenin interaction in stem cells, 240–241
 embryonic stem cell self-renewal, 235, 238
- Odonto-onycho-dermal dysplasia, Wnt signaling, 338
- OPPG. *See* Osteoporosis pseudoglioma syndrome
- Osteoblast, Wnt/ β -catenin signaling
 differentiation and maturation, 270–271
 function, 272–274
- Osteocyte, Wnt/ β -catenin signaling, 274–275
- Osteoporosis, Wnt/ β -catenin signaling mutations, 268–269
- Osteoporosis pseudoglioma syndrome (OPPG), Wnt/ β -catenin signaling, 268–269, 432
- Oto, Wnt processing, 28
- P**
- Patterning. *See* Axis specification
- PCP. *See* Planar cell polarity
- Phenylmethimazole, Wnt signaling effects, 438
- Planar cell polarity (PCP)
 β -catenin-independent Wnt signaling, 128–129, 135–136
 core proteins, 135
 effectors, 135–136
 Frizzled role, 66
 mouse non-canonical Wnt signaling
 epiblast cell polarity, 223–224
 hair follicle orientation, 225
 limb development, 226–228
 morphogenesis, 225
 neural tube closure, 225
 nodal cilia, 224
 overview, 223
 stereociliary bundle orientation, 224–225
- POP1, 116, 185, 190–191
- PORCN, 28, 34
- Porcupine
 Caenorhabditis elegans, 182
 history of study, 13
- Prickle, 135
- Prostaglandins, Wnt cross-talk in cancer, 399–400
- PSD95, 289
- Pyridinium, Wnt signaling inhibition, 433
- Pyruvate kinase, Wnt cross-talk in cancer, 400
- R**
- RA. *See* Rheumatoid arthritis
- Rac, β -catenin-independent Wnt signaling, 135–136
- Radial glia. *See* Central nervous system
- Regeneration. *See* Injury repair
- Rheumatoid arthritis (RA), Wnt signaling and therapeutic targeting, 431
- Rho, β -catenin-independent Wnt signaling, 135–136
- Rhomboid, 166
- Riluzole, melanoma trials, 438
- ROR
 β -catenin-independent Wnt signaling, 133–134
 history of study, 13
- Rspo. *See* R-spondin
- R-spondin (Rspo)
 cancer role, 55
 developmental function
 female sex determination and Rspo1, 54
 limb, craniofacial, and lung development, 54
 nail development and Rspo4, 55
 vasculature and Rspo3, 54–55
 injury repair therapeutic application, 416–417
 knockout mice, 44–45
 Lgr receptor mediation of signaling in stem cells, 259–260
 mechanism of action, 52–54
 structure, 52
- Ryk
 β -catenin-independent Wnt signaling, 134
 topographical map formation in brain, 285–287
- S**
- Schizophrenia, Wnt signaling, 293, 426
- Sclerostin (SOST)
 bone disease mutations, 268–266
 knockout mouse, 44, 437
 overview, 49

- Secreted Frizzled-related proteins (SFRPs)
 Caenorhabditis elegans, 183
 developmental function, 47–48
 implantation role in mouse, 218
 knockout mice, 44
 mechanism of action, 46–47
 structure, 46
 therapeutic targeting, 437
 tumor suppression, 47
- SFRPs. *See* Secreted Frizzled-related proteins
- Shisa
 knockout mice, 44
 Wnt signaling inhibition, 50–51
- Skin, Wnt signaling
 anatomy, 320
 development, 319–322, 328
 diseases, 337–338
 hair follicle cycling changes, 328–333
 interfollicular epidermis, 333–335
 melanocyte, 335–337
 mouse mutation models, 323–327
 prospects for study, 338–339
- SLE. *See* Systemic lupus erythematosus
- Smoothened, 66
- Sociology, Wnt research, 14–16
- Somitogenesis, mouse Wnt signaling, 222–223
- SOSDC. *See* Wise
- SOST. *See* Sclerostin
- Sox2, embryonic stem cell self-renewal, 235
- Stem cells. *See* Cancer stem cell; Embryonic stem cell; Hematopoietic stem cell; Intestinal stem cell; Lgr5; Mammary gland
- Stomach
 cancer stem cells, 259
 gastric stem cells, 257–258
 human versus mouse, 251–252
- Synapse. *See* Central nervous system
- SYS-1, 184–185
- Systemic lupus erythematosus (SLE),
 Wnt signaling and therapeutic targeting, 431
- T**
- Tail bud, mouse Wnt signaling, 222–223
- Tankyrase, therapeutic targeting, 435
- T cell, Wnt signaling in development, 314–315
- T-cell factor. *See* TCF/LEF
- TCF/LEF
 axis specification and TCF function regulation, 203–204
 β -catenin-binding domain, 106–107
 Caenorhabditis elegans, 185–186
 canonical Wnt signaling outside of TCF/LEE, 118–119
- C clamp, 107–108
DNA-binding domain, 106
embryonic stem cell
 Tcf3 in self-renewal, 241–242
 Wnt-stabilized β -catenin in Tcf-dependent mechanisms, 242–246
evolution, 109
expression regulation, 114–118
Groucho/transducin-like enhancer of split-binding domain, 108–109
histone modification regulation, 112–114
history of study, 13
intestinal stem cell maintenance by TCF4, 16
isoforms, 109–110, 115
LEF-1
 forebrain patterning, 300–301
 melanocyte function, 335
overview, 105–106
TCF4, cancer mutations, 397
therapeutic targeting, 434–436
transcriptional switch, 110–112
- Tiki1, Wnt signaling inhibition, 51–52
- TNIK, phosphorylation of TCF/LEE, 116–117
- V**
- Vangl*, 226–227
- VDR. *See* Vitamin D receptor
- Vestigial (Vg), 169
- Vg. *See* Vestigial
- Vitamin D receptor (VDR), β -catenin binding, 119
- Vps26, 31
- Vps35, 31
- W**
- Waif1/5T4. *See* Wnt-activated inhibitory factor-1
- WIF1. *See* Wnt inhibitory factor-1
- Wingless
 developmental genetics, 6–7
 embryo signaling, 164–168
 gradient formation, 171–172
 morphogen activity, 169–171
 mutants, 167
 neuromuscular junction development, 382, 385–387
 prospects for study, 173
 target genes, 172–173
 vertebrate Wnt comparison, 164
 wing imaginal disc signaling, 168–169
- Wise
 knockout mice, 44
 overview, 48–49
- Wls. *See* *Wntless*

Index

Wnt

agonists and antagonists. *See also specific modulators*

protein studies, 33

small molecule studies, 34

β -catenin-independent signaling

development, 128–129, 135–136

mechanisms, 129–135

canonical signaling overview, 65–66

Drosophila. *See* Wingless

evolution of pathway. *See* Evolution, Wnt pathway

extracellular interactions, 32–33

genes and protein product prediction, 26–27

Int1 history of study, 3–8

intracellular processing, 27–28

purification, 13–14, 33

secretion, 30–32

signaling cascade from cell surface to nucleus,
10–11

structure, 28–29

therapeutic targeting

activation strategies, 436–438

autoimmune disease and inflammation,
430–431

β -catenin-independent signaling, 438

cancer, 424–426

clinical trials, 429–430

inhibitors

downstream signaling inhibition,
435–436

identification, 433–434

overview, 429, 432–433

proximal signaling inhibition, 434–435

neurologic disease, 426, 430

regenerative medicine, 431–432

tissue functions. *See specific tissues*

Web page, 16

Wnt1 gene evolution and development in
metazoans, 8–9

Wnt-activated inhibitory factor-1 (Wain1/5T4)

knockout mice, 44

Wnt signaling inhibition, 51

Wnt inhibitory factor-1 (WIF1)

knockout mice, 44

overview, 31, 48

Wntless (Wls), 30–32, 182, 386

Wound healing. *See* Fracture; Injury repair

Z

ZNRF3, 53–54